Compile Data Set for Download or QSAR
Report error Found 18 Enz. Inhib. hit(s) with all data for entry = 551
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3690(8-N-(3-bromophenyl)-2-N-[2-(1H-imidazol-4-yl)ethyl...)
Affinity DataIC50: 0.25nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3684(8-N-(3-bromophenyl)-2-N-methyl-[1,3]diazino[5,4-d]...)
Affinity DataIC50: 0.760nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3688(4-[(3-Bromophenyl)amino]-6-[[2-(4-morpholino)ethyl...)
Affinity DataIC50: 0.810nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3685(4-[(3-Bromophenyl)amino]-6-(dimethylamino)pyrimido...)
Affinity DataIC50: 0.950nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3683(6-Amino-4-[(3-bromophenyl)amino]pyrimido[5,4-d]pyr...)
Affinity DataIC50: 1.5nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3696(4-[(3-Methylphenyl)amino]-6-[[2-(4-morpholino)ethy...)
Affinity DataIC50: 2.30nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3691(4-[(3-Bromophenyl)amino]-6-[[3-(1-imidazolyl)propy...)
Affinity DataIC50: 2.30nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3689(8-N-(3-bromophenyl)-2-N-[3-(morpholin-4-yl)propyl]...)
Affinity DataIC50: 2.90nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3697(4-[(3-Methylphenyl)amino]-6-[[2-(4-imidazolyl)ethy...)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3686(N-(3-bromophenyl)-6-methoxy-[1,3]diazino[5,4-d]pyr...)
Affinity DataIC50: 3.80nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3695(6-(Dimethylamino)-4-[(3-methylphenyl)amino]pyrimid...)
Affinity DataIC50: 4nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3694(2-N-methyl-8-N-(3-methylphenyl)-[1,3]diazino[5,4-d...)
Affinity DataIC50: 4.30nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3681(2-N-methyl-8-N-phenyl-[1,3]diazino[5,4-d]pyrimidin...)
Affinity DataIC50: 13nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3693(6-Amino-4-[(3-methylphenyl)amino]pyrimido[5,4-d]py...)
Affinity DataIC50: 17nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3687(8-N-(3-bromophenyl)-2-N-[2-(dimethylamino)ethyl]-[...)
Affinity DataIC50: 35nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3682(4-[(3-Bromophenyl)amino]-6-chloropyrimido[5,4-d]py...)
Affinity DataIC50: 82nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3692(4-[(3-Methylphenyl)amino]-6-chloropyrimido[5,4-d]p...)
Affinity DataIC50: 380nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
University of Auckland

LigandPNGBDBM3680(6-Chloro-4-(phenylamino)pyrimido[5,4-d]pyrimidine ...)
Affinity DataIC50: 2.55E+3nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2005
Entry Details Article
PubMed